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The genetic background of complex diseases is proposed to consist of several low-penetrance risk loci. Addressing this
complexity likely requires both large sample size and simultaneous analysis of different predisposing variants. We
investigated the role of four thrombosis genes: coagulation factor V (F5), intercellular adhesion molecule 1 (ICAM1),
protein C (PROC), and thrombomodulin (THBD) in cardiovascular diseases. Single allelic gene variants and their pair-
wise combinations were analyzed in two independently sampled population cohorts from Finland. From among 14,140
FINRISK participants (FINRISK-92, n¼5,999 and FINRISK-97, n¼8,141), we selected for genotyping a sample of 2,222,
including 528 incident cardiovascular disease (CVD) cases and random subcohorts totaling 786. To cover all known
common haplotypes (.10%), 54 single nucleotide polymorphisms (SNPs) were genotyped. Classification-tree analysis
identified 11 SNPs that were further analyzed in Cox’s proportional hazard model as single variants and pair-wise
combinations. Multiple testing was controlled by use of two independent cohorts and with false-discovery rate. Several
CVD risk variants were identified: In women, the combination of F5 rs75422813THBD rs1042580, together with three
single F5 SNPs, was associated with CVD events. Among men, PROC rs1041296, when combined with either ICAM1
rs5030341 or F5 rs2269648, was associated with total mortality. As a single variant, PROC rs1401296, together with the
F5 Leiden mutation, was associated with ischemic stroke events. Our strategy to combine the classification-tree
analysis with more traditional genetic models was successful in identifying SNPs—acting either in combination or as
single variants—predisposing to CVD, and produced consistent results in two independent cohorts. These results
suggest that variants in these four thrombosis genes contribute to arterial cardiovascular events at population level.
Citation: Auro K, Alanne M, Kristiansson K, Silander K, Kuulasmaa K, et al. (2007) Combined effects of thrombosis pathway gene variants predict cardiovascular events. PLoS
Genet 3(7): e120. doi:10.1371/journal.pgen.0030120
Introduction
The genetic basis of complex diseases like coronary heart
disease and ischemic stroke probably consists of several
predisposing risk factors that can interact with environ-
mental factors to produce the disease phenotype. To address
such polygenic structure is a challenge likely requiring
simultaneous analysis of several risk factors, including genetic
variants, in large study samples rich in phenotypes. Gene–
gene and gene–environment interaction studies have recently
attempted to answer this challenge by analyzing the interact-
ing relations of putative risk loci [1–5]. The majority of these
studies, however, use two to three genetic markers, thus
failing to address the physiological entities or the underlying
complex genetic proﬁles.
In a physiological clotting cascade, binding of thrombin to
its receptor, thrombomodulin (THBD), activates protein C
(PROC). Activated protein C cleaves coagulation factor V (F5)
[6], leading to ﬁbrinolysis. Genetic variation in the cascade
genes predisposes to increased clotting, the best known
example being activated protein C resistance caused by the
factor V Leiden mutation [7]. Several case reports describe
PROC deﬁciency in patients with arterial thrombosis [8,9].
Activated protein C may also play a neuroprotective role in
ischemic stroke [10,11]. THBD and intercellular adhesion
molecule 1 (ICAM1) are markers for endothelial activation
and damage [12]. Low concentrations of soluble THBD,
especially when present along with elevated soluble ICAM1,
predispose to cardiovascular disease (CVD) events [13,14].
Whether THBD gene variants act as independent CVD risk
factors remains unclear [15].
Studies on these four genes have mainly concentrated on a
few, often rare, functional polymorphisms within the indi-
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variants of several genes encoding components of the same
physiological cascade will prove to be a more powerful
approach to shedding light on CVD risk mechanisms than are
studies on single candidates. Analyses comprising several
genes belonging to the same pathway may reveal cumulative
allelic effects. When acting together, these gene variants may
affect the disease risk more profoundly than do the single
predisposing variants. We covered common variants of F5,
ICAM1, PROC, and THBD genes and assessed their role in
CVD in two prospective and independently sampled pop-
ulation cohorts of Finns. To address the single gene variants
and their interplay in cardiovascular traits, we chose a two-
step strategy. We ﬁrst aimed to identify the variants
contributing most to the CVD risk in our study sample using
classiﬁcation-trees. Second, based on these analyses, we
studied a subset of the most important SNPs by classical
genetic analyses, ﬁrst as independent markers and then as
pair-wise combinations as deviation from the multiplicative
model of genetic interaction. Our study identiﬁed several
variants predisposing to CVD as single or cooperating
markers.
Materials and Methods
Study Samples
We utilized two large, independently sampled, and pro-
spectively followed population cohorts from Finland, FIN-
RISK-92 (n ¼ 5,999, follow-up 1992–2001) and FINRISK-97 (n
¼ 8,141, follow-up 1997–2003). Subjects for genotyping were
selected according to a case-cohort design from among
14,140 FINRISK participants. As cases in this study, we
consider those with an incident coronary event (coronary
heart disease [CHD], n ¼ 401) or ischemic stroke (n ¼ 149)
during follow-up and did not have acute coronary events or
strokes before the baseline examination, and everyone
deceased from any reason during follow-up (n ¼ 610). In
addition, individuals having experienced cardiovascular
events at baseline were genotyped, but baseline CVD was
not utilized as an endpoint in this study. International
Classiﬁcation of Diseases (ICD)  9 and  10 codes for fatal
coronary events were 410–414 and 798, and I20–I25, I46, R96,
R98, R99, and for nonfatal coronary events 410–411 (ICD-9)
and I20.0 and I21–I22 (ICD-10). For fatal and nonfatal
ischemic strokes, ICD-9 codes 433 (excluding 4330X, 4331X,
and 4339X of the Finnish modiﬁcation of ICD-9), 434
(excluding 4349X), and ICD-10 code I63 were used. The
ICD-10 revision has been used in Finland since January 1996.
We will denote the combination of coronary event and
ischemic stroke endpoints by CVD. Because 21 individuals
h a db o t ha ni n c i d e n tc o r o n a r ye v e n ta n da ni n c i d e n t
ischemic stroke, the total number of individuals having
incident CVD events was 528. Of the 610 deceased, 138 also
had an incident CVD event. Random subcohorts, selected
with age-dependent probabilities, were drawn from the
original cohorts to represent the general study populations
(FINRISK-92 n ¼ 400, FINRISK-97 n ¼ 386). Thus, the
subcohorts also included individuals having CVD events at
baseline (n ¼ 88) or during follow-up (n ¼ 72). This selection
yielded a study sample of 2,222 individuals for genotyping
(Table 1). Information on the traditional CVD risk factors
(serum cholesterol, triglyceride (TG), and C-reactive protein
(CRP) levels, blood pressure, anthropomorphic measures,
smoking, medication, disease, and family history) as well as
whole blood samples for DNA were collected at baseline. The
study cohorts have been described in detail previously [15,20]
and at http://www.ktl.ﬁ/publications/morgam/cohorts/index.
html. The Ethics Committee of the National Public Health
Institute of Finland approved the study.
Genotyping Strategy
To cover all known common (frequency .10%) variants in
the four thrombosis genes, 54 single nucleotide polymor-
phisms (SNPs) were selected: 24 SNPs in F5, nine in ICAM1,
seven in PROC, and 14 in THBD [15]. This selection was based
on haplotype information in the SeattleSNPs variation
discovery resource [21]. The F5 Leiden mutation (rs6025)
was included based on the literature. Haplotype structures in
the four genes were analyzed with Haploview3.2 [22]. For any
two SNPs in tight linkage disequilibrium (LD, r
2 . 0.8) with
each other, only one was included in further analyses.
Because SNP selection was based on haplotype information,
haplotype analyses were excluded. Baseline CVD cases were
utilized in LD calculations, but had to be excluded from
Cox’s proportional hazard model due to the unknown time of
the event measured (before the study began). Thus, the
baseline cases were excluded from all statistical analyses to
achieve a similar study sample used in all the analyses.
Rs3216183 was genotyped with TaqMan (Roche Molecular
Systems, http://www.roche.com/) and the remaining 53 SNPs
with Sequenom MassARRAY (Sequenom, http://www.
sequenom.com/) with 10 ng of DNA and hME chemistry.
Primer information and assay conditions are available from
the authors upon request. DNA was extracted by standard
protocols [23] from whole blood stored at 20 8C. ICAM1 SNP
r5030380 was excluded due to technical difﬁculties. The
samples with low DNA yield (n ¼ 100) were whole-genome
ampliﬁed before genotyping [24]. Before genotyping the
FINRISK samples, the Mendelian inheritance of each SNP
was checked in a Finnish sample of 60 mother, father, and
child trios. Mendel check revealed no errors. The FINRISK
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Author Summary
The genetic background of cardiovascular diseases is still largely
unknown. As in other complex diseases, the genetic risk is thought
to consist of several genetic variants and their possible interactions.
Elucidation of the genetic component of any complex trait most
likely requires simultaneous examination of various genes in large
and well-characterized study samples. Our study explores the role in
cardiovascular disease of four thrombosis genes: coagulation factor
V, intercellular adhesion molecule 1, protein C, and thrombomodu-
lin. These genes form a physiological pathway that is part of the
coagulation cascade. Their defects, such as the Leiden mutation in
factor V gene, predispose to venous thrombosis, making them
tempting candidates for involvement with cardiovascular events.
Given the interactions of these genes at the molecular level, a logical
way to explore their genetic effects is simultanous rather than gene-
specific analysis of all the four genes, aiming to illustrate their
possible interplay. The study setting combines classification trees
with classic genetic analyses and covers all known common variants
of the genes. The results imply that the variants in these four genes
contribute to disease risk either alone or in various allelic
combinations.genotypic sample included 2% open and 5% blinded
duplicates. Genotyping was performed as part of the
MORGAM and GenomEUtwin Projects (http://www.
genomeutwin.org/) [25]. The genotyping error rate was ,1/
400 in blind duplicate comparisons. The genotyping success
rate was 93% or higher for each SNP. Together, these
quality-control -procedures suggested very high genotyping
quality.
Statistical Analyses
Statistical analyses were performed in three stages: (1) with
AnswerTree3.0 (SPSS, http://www.spss.com/) to discover pos-
sible co-appearance of allelic variants as risk deﬁners and to
select the most signiﬁcant SNPs for further analyses, and (2)
with SAS v8.2 for Windows (SAS, http://www.sas.com/) to
estimate allele frequencies, to discover SNPs inﬂuencing the
traditional CVD risk factors, and to estimate hazard ratios
(HR) of the SNP alleles with Cox’s proportional hazards
model [26]. (3) Finally, to estimate whether the SNPs chosen
at stage 1 were the informative ones required a separate
sensitivity analysis. All SNPs were analyzed in Cox’s propor-
tional hazards, coding the SNPs as 1–0 assuming dominant
inheritance.
AnswerTree is a classiﬁcation-tree algorithm that attempts
to ﬁnd a variable and a cutpoint for the variable to split a
dataset to best predict disease outcome. This split is called the
root node. The algorithm is then applied to the resulting
subgroups of the dataset accordingly, and the process is
continued to form a tree. In our application of the algorithm,
SNPs were coded as 0 (minor allele carriers) to 1 (major allele
homozygotes) assuming dominant inheritance and analyzed
together with the traditional risk factors, using incident CVD
events as the endpoint. Of the possible algorithms we used
exhaustive chi-squared automatic interaction detector
(CHAID), which allows more than two sister nodes in a split
if necessary and thus was thought to model the biological risk
caused by the phenotypic risk factors, for example cholesterol
values, better than a strictly bifurcated split, and moreover, it
allows control of a number of steps in the tree: To keep the
tree structure simple and to discover combinations of
predisposing factors affecting relatively large groups of
individuals, we set the minimum root node size at 20 and
the minimum end node size at 10. Maximum branch level in
the trees was limited to ﬁve. The signiﬁcance of all splits was
calculated as v
2
To search for all well-supported splits and to reduce the
extent to which the root node in the overall analysis may
obscure other important splits we decided, instead of growing
a single tree, to grow a forest of trees: a collection of
classiﬁcation trees achieved by bootstrap techniques using
random subsamples and other criteria. In order to grow the
forest, we took ten random subsamples of 60% of the men
and ten random subsamples of 60% of the women of the
combination of the FINRISK-92 and  97 cohorts. First, one
tree was grown for each subsample to determine the
signiﬁcant splits. These 20 trees included altogether 50
signiﬁcant splits for men and 45 for women (Tables 1 and
2). Using these signiﬁcant splits from the 20 trees as root
nodes we grew a forest of 50 trees for men and 45 trees for
women still utilizing the subsample data. The SNPs present in
.10% of the sex-speciﬁc trees were selected for further
analysis. Because the data used in the classiﬁcation-tree
analysis originated from a single dataset, combining the two
cohorts, no cross validation among the samples was
performed.
At stage 2, we ﬁrst used the combined data set of FINRISK-
92 and  97 cohorts to gain maximum power, but also both
cohorts separately to assess the consistency of the ﬁndings.
The allele distributions of the selected SNPs between the
cases and the subcohort (excluding cases and baseline CVD)
were compared with Pearson’s v
2. The relation of each SNP to
the common CVD risk factors (TG, total cholesterol [TC],
HDL cholesterol [HDL], TC/HDL ratio, systolic and diastolic
blood pressure, CRP, body mass index [BMI], and waist-to-hip
ratio [WHR]) was analyzed separately for each risk factor with
an age-, sex-, and cohort-adjusted general linear model. To
achieve normality, HDL and CRP were log transformed.
Hazard ratios for all selected SNPs and their pair-wise
combinations (with interaction terms, as deviation from the
multiplicative model of interaction) were calculated with
Cox’s proportional hazards model, with age at baseline, (sex),
TC/HDL ratio, BMI, smoking, diabetes, hypertension, and
CRP as covariates. Time from baseline served as the time
parameter. The analysis was stratiﬁed by eastern and western
Finland and additionally by cohort when combining the two
datasets. Total mortality, incident coronary, incident ische-
mic stroke, and incident CVD (coronary and stroke events
combined) events served as endpoints. We ﬁrst performed
sex-speciﬁc analyses and then combined men and women,
under additive, dominant, and recessive inheritance models.
Table 1. Characteristics of the Study Cohorts: Number of Cardiovascular Events
Event Type FINRISK-92 FINRISK-97 Total
All Men
(n ¼ 2,833)
Men Subcohort
a
(n ¼ 286)
All Women
(n ¼ 3,166)
Women
Subcohort
a
(n ¼ 114)
All Men
(n ¼ 4,092)
Men Subcohort
a
(n¼304)
All Women
(n ¼ 4,049)
Women
Subcohort
a
(n ¼ 82)
Baseline CVD 159 29 63 3 322 50 118 6 662
Incident CVD event 143 30 53 4 156 14 49 3 401
Incident stroke 35 8 33 3 59 10 21 2 148
Total mortality 188 34 94 9 242 35 86 8 610
aA subcohort is a random sample of the full cohorts selected for genotyping
n, number.
doi:10.1371/journal.pgen.0030120.t001
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model, due to low minor allele frequency. Multiple testing
was addressed by performing all analyses in the two separate
cohorts, as well as with false-discovery rate (FDR). FDR was
calculated within sex- and endpoint-speciﬁc groups. SNP
combinations were analyzed with interaction terms as
deviation from the multiplicative model (i.e., interaction
HR different from the product of the independent SNP HRs)
in Cox’s model adjusted for the same risk factors as with the
single SNPs. With interaction terms, the recessive model of
inheritance was selected for a SNP if it showed signiﬁcant
association in the single SNP analyses, otherwise the
dominant model was used to gain power. Results showing a
consistent association or similar trend in the two separate
study cohorts or their combination or both, and having FDR
,0.1 for their combination were considered as signiﬁcant.
Results
In both cohorts and in both sexes incident CVD cases had
higher total cholesterol and BMI and lower HDL cholesterol
at baseline than did subcohort members free of CVD at the
end of follow-up. The CVD cases also had a higher frequency
of diabetes and hypertension and more often smoked than
did the healthy subcohort members (Table 3). The baseline
characteristics of the cases and the subcohorts have been
described in detail [15,20].
Based on analyses with Haploview3.2, the LD pattern of our
study sample of Finns, a population isolate known to retain
higher levels of LD [27], differed from that provided by
Seattle SNPs, and we excluded from the analyses four F5 SNPs
(rs3766103, rs2227245, rs6670678, and rs6029, Figure S1), one
ICAM1 SNP (rs5030352), one PROC SNP (rs2069921), and one
THBD SNP (rs1042579), all showing strong LD (r
2   0.8) with
another SNP. In addition, SNPs monomorphic in 370 Finnish
individuals were excluded (rs5030388, rs9332566, rs9332625,
rs9332587, rs1046712, rs1800576, rs1800577, rs1800578,
rs1800579, rs3176122, and rs3176121). The genotype frequen-
cies of the remaining 36 SNPs (Table S2) followed Hardy–
Weinberg equilibrium in the subcohorts (p . 0.05).
We aimed to reduce the number of variants used in further
analyses and to discover possible co-effects of single gene
variants by classiﬁcation-tree analyses. The 36 SNPs, together
with the baseline phenotypic variables (smoking, TC, TG,
HDL, BMI, WHR, systolic and diastolic blood pressure,
diabetes status, and CRP), were analyzed with AnswerTree3.0
with incident CVD as an endpoint. We grew a forest of
classiﬁcation-trees using each of the signiﬁcant splits of Table
2 and Table S1 as root nodes. From this 95-tree forest (50
trees for men and 45 for women), we selected all SNPs present
in .10% of the trees for further analyses. This selection
yielded 12 SNPs: six F5 SNPs and two SNPs each from THBD,
PROC, and ICAM1. Of the F5 SNPs, rs970741 was excluded
due to relatively strong LD (r
2 ¼ 0.42) with rs2420369 (Figure
S1), further reducing the SNP selection to 11 (Table 4). The
rationale for this exclusion was to avoid an LD-based bias
when analyzing SNP combinations. Figure 1 gives an example
of a single tree grown with a random female sample. The
ﬁgure also demonstrates a general pattern observed: the best
splits seen with all subsamples were traditional phenotypic
risk factors such as cholesterol or BMI, and the SNPs played a
role in the lower branches of the trees, i.e., in subgroups of
individuals speciﬁed by the phenotypic factors (Figure 1,
Table 2, Table S1).
Next, we analyzed genotype–phenotype relationships of the
11 selected SNPs under additive, dominant, and recessive
models of inheritance. The male minor allele carriers of
ICAM1 rs5030341 had signiﬁcantly smaller waist-to-hip ratio
(p¼0.0077 for combined cohorts, data not shown) than did the
non-carriers of this allele, and the CVD cases homozygotic for
F5 rs7542281 had signiﬁcantly lower BMI (p ¼ 0.0018 for
combined cohorts, unpublished data). These observations
were consistent in both cohorts.
Separate Cox’s proportional hazard models were ﬁtted for
all selected 11 SNPs and their pair-wise combinations.
Incident coronary, incident ischemic stroke, incident cardi-
ovascular events, and total mortality served as endpoints. We
Table 2. Significant Splits (Sample-Specific p-Value, v
2) Seen in Classification-Trees Grown in AnswerTree3.0 with Ten Random Female
Datasets, Each Containing 60% of the Original Data
Variable Tree Number
12 34 5 6 7 89 1 0
Diabetes 0.00051 0.016 0.00015 0.0077 0.035 0.0019 0.0056 0.0043 0.0042 0.032
BMI — — 0.014 — — 0.021 — — 0.0013 —
WHR 0.0091 — — — — 0.048 — — — —
HDL 0.0023 0.0025 0.00055 0.0058 0.000068 — 0.035 0.00090 0.000081 0.0029
TC/HDL — 0.020 0.0041 0.014 0.014 — — 0.0037 0.00039 0.037
TG 0.0098 0.0022 — 0.0011 — — 0.021 0.013 — —
Non-HDL — — — — — — — 0.025 — —
Smoking — — 0.0095 — 0.024 — 0.016 — — —
Hypertension — — — — — — — — 0.0032 —
Rs2269648 0.012 — — — — — — — — —
Rs7542281 — 0 . 0 4 0 — —— ——— — —
Rs9332575 — — 0 . 0 1 0 — —— — — ——
Rs1042580 — — — — — — 0.031 — — —
SNPs are analyzed as 0 (minor allele carriers) to 1 (major allele homozygotes).
doi:10.1371/journal.pgen.0030120.t002
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separate cohorts or their combination or both, and exceeding
the FDR ,10% limit for the combined cohorts as signiﬁcant.
With pair-wise SNP combinations, a notable deviation from
the multiplicative interaction model was additionally re-
quired. The Cox’s model revealed several signiﬁcant CVD risk
variants (Tables 3, 5, and 6). Among women, F5 SNPs
rs7542281 was associated with incident CVD. When combined
with THBD rs1042580, substantial deviation from multi-
plicative model of interaction was seen. In addition, F5
rs2420369 was associated with incident CVD events. In men,
PROC rs1401296 was associated with total mortality when
combined with ICAM1 rs5030341 or with F5 rs2269648.
ICAM1 rs5030347 was associated with total mortality as a
single variant.
In analysis of coronary events and ischemic strokes
separately, F5 SNP rs7542281 showed an association with
both coronary and ischemic stroke events as a single variant
in women, and F5 rs2269648 was associated with incident
ischemic stroke. In men, PROC rs1401296, together with F5
Leiden mutation, was associated with incident ischemic
stroke. The wide conﬁdence intervals seen when analyzing
stroke events in females reﬂect the small number of female
stroke cases. Several other SNPs showed a suggestive
association with the endpoints, but failed the FDR ,0.1
criterion (Tables 5 and 6). Figure 2 shows a schematic
overview of the contribution of the gene variants analyzed
here to CVD.
T h ei m p o r t a n c eo ft h eS N P se x c l u d e df r o mf u r t h e r
analyses was assessed by analysis of all the 36 SNPs with
Cox’s proportional hazards model, assuming dominant
inheritance, using combined cohorts in all the data and then
Table 4. Minor Allele Frequencies of the SNPs Analyzed in Stage 2 of the Study
SNP Gene Position
(Amino Acid Change)
FINRISK-92 FINRISK-97
Men CVD
a
(n ¼ 170)
Men
Subcohort
(n ¼ 220)
Women CVD
a
(n ¼ 86)
Women
Subcohort
(n ¼ 104)
Men CVD
a
(n ¼ 204)
Men
Subcohort
(n ¼ 332)
Women CVD
a
(n ¼ 68)
Women
Subcohort
(n ¼ 71)
Rs2269648 F5 Promoter 0.24 0.28 0.23 0.30 0.27 0.25 0.24 0.29
Rs2420369 F5 Intron 0.37 0.38 0.31 0.42 0.41 0.36 0.36 0.42
Rs7542281 F5 Intron 0.37 0.34 0.36 0.26 0.32 0.35 0.43 0.33
Rs9332591 F5 Intron 0.12 0.13 0.11 0.13 0.10 0.12 0.13 0.17
Rs6025
b F5 Exon (Q/R) 0.03 0.03 0.03 0.01 0.03 0.01 0.03 0.03
Rs5030341 ICAM1 Intron 0.33 0.33 0.37 0.38 0.30 0.34 0.34 0.37
Rs5030347 ICAM1 Intron 0.23 0.21 0.23 0.16 0.23 0.18 0.24 0.17
Rs5937 PROC Exon (D/D) 0.27 0.30 0.31 0.26 0.26 0.29 0.25 0.28
Rs1401296 PROC 39 0.34 0.31 0.31 0.34 0.37 0.35 0.38 0.39
Rs1042580 THBD 39 0.30 0.30 0.32 0.29 0.37 0.36 0.33 0.31
Rs6048519 THBD Promoter 0.43 0.43 0.44 0.46 0.43 0.48 0.45 0.37
Cardiovascular cases removed from the subcohorts.
aCVD: incident coronary event or ischemic stroke during follow-up.
bF5 Leiden mutation.
doi:10.1371/journal.pgen.0030120.t004
Table 3. Characteristics (Mean [Standard Deviation] or %) of the Study Cohorts
Variable FINRISK-92 FINRISK-97
Men CVD
a
(n ¼ 170)
Men
Subcohort
(n ¼ 220)
Women CVD
a
(n ¼ 86)
Women
Subcohort
(n ¼ 104)
Men CVD
a
(n ¼ 204)
Men
Subcohort
(n ¼ 231)
Women CVD
a
(n ¼ 68)
Women
Subcohort
(n ¼ 71)
Age (years) 54.2 (7.7) 52.8 (9.1) 54.9 (8.0) 55.9 (6.7) 61.9 (8.7) 59.9 (10.2) 62.8 (7.4) 63.1 (7.6)
BMI (kg/m
2) 28.6 (3.9) 27.4 (3.9) 29.3 (5.1) 26.9 (4.7) 28.6 (3.5) 27.5 (3.9) 29.3 (4.5) 27.9 (4.4)
WHR 0.97 (0.06) 0.95 (0.07) 0.84 (0.07) 0.80 (0.06) 0.97 (0.06) 0.99 (0.06) 0.84 (0.07) 0.83 (0.07)
TC (mmol/l)
b 6.3 (1.1) 5.8 (1.0) 6.1 (1.3) 6.0 (1.0) 5.8 (1.0) 5.7 (1.0) 6.1 (0.9) 6.0 (1.1)
HDL (mmol/l) 1.2 (0.3) 1.3 (0.4) 1.4 (0.4) 1.6 (0.4) 1.2 (0.3) 1.3 (0.3) 1.4 (0.4) 1.5 (0.4)
CRP (mg/l) 4.31 (5.46) 2.58 (3.86) 3.58 (4.79) 1.00 (3.99) 2.90 (3.24) 1.93 (2.37) 3.30 (3.87) 2.65 (4.23)
Diabetes (%) 9.4 4.5 15.3 3.8 13.7 5.6 17.6 7.0
Hypertension (%) 70.6 54.5 78.8 63.5 75.0 65.4 67.6 74.6
Smoking (%) 39.4 24.5 16.5 9.6 27.0 23.4 20.6 11.3
Outliers þ/  four standard deviations excluded. CVD cases removed from the subcohorts.
aCVD: incident coronary event or ischemic stroke during the follow-up.
bIndividuals with cholesterol-lowering medication removed from lipid analyses.
doi:10.1371/journal.pgen.0030120.t003
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two-stage approach was able to recognize all informative
SNPs: the signiﬁcant results (p , 0.05) seen in Cox’s model
were concentrated in those SNPs selected for stage 2. With all
the other SNPs showing statistical signiﬁcance for the
combined cohorts, the results from the separate study cohorts
showed either a discrepancy in the hazard ratio or only one of
the cohorts gave a signal (Tables S4–S16).
Discussion
Our present study provides a fresh way to utilize different
methods to analyze the impact of multiple genes on a
phenotype. This two-step analysis strategy used classiﬁcation-
trees to select a subset of SNPs from a larger set of genome-
wide haplotype tagging SNPs for further genetic analyses of
allelic covariance and hazard ratios. The importance of the
SNPs excluded from the further analyses was assessed with a
separate sensitivity analysis. Even though all genetic variants,
or combinations of them, were required to show consistent
effects in both the independent cohorts to be considered
signiﬁcant, only functional studies and replications in other
populations will validate the importance of these ﬁndings for
CVD. This may prove a valuable approach in whole-genome
association analyses, where the amount of genetic data is
overwhelming.
Classiﬁcation-trees structure data by searching ﬁrst for the
variable best explaining the determined endpoint and
splitting the dataset into subgroups according to this variable.
The search continues in the speciﬁed subgroups, which again
split into smaller groups accordingly. Classiﬁcation-trees are
thus useful in organizing noisy datasets comprising multiple
variables, and can be used to identify speciﬁc pathways
determining an outcome or speciﬁc subgroups having
similarities leading to this outcome. Gruenewald et al. [28]
utilized classiﬁcation-trees to identify risk markers for
mortality in an elderly population, and determined several
mortality-predictive pathways consisting of different combi-
nations of markers, in both men and women. Their study
highlights the multiplicity of solutions leading to the same
outcome and illustrates how classiﬁcation-trees can prove
useful in structuring multiple variables in an organized
manner. In our data, the classiﬁcation-tree analysis itself
failed to detect consistent gene–gene or gene–environment
interaction patterns, but was useful in reducing the number
of SNPs analyzed with other models. In our dataset, the forest
of trees demonstrated that the inﬂuence of any tested SNP on
Figure 1. Example of a Classification-Tree in a Random Female
Subsample Consisting of 60% of the Original Data
SNPs are analyzed as 0 (minor allele carriers) to 1 (major allele
homozygotes), modeling dominant inheritance.
doi:10.1371/journal.pgen.0030120.g001
Table 5. Association of Single SNPs with the Endpoints in Time-to-Event Analysis
SNP Gene Inheritance Model Group FINRISK-92 FINRISK-97 Combined FDR
c
HR (CI 95%) p-Value HR (CI 95%) p-Value HR (CI 95%) p-Value
Rs7542281 F5 Additive
a CHD, women 2.82 (0.94–8.49) 0.065 3.21 (1.30–7.93) 0.011 2.63 (1.38–5.00) 0.0033 þ
Rs7542281 F5 Additive
a CVD, women 3.98 (1.65–9.56) 0.0021 2.63 (1.11–6.23) 0.028 2.65 (1.50–4.39) 0.00061 þ
Rs2420369 F5 Additive
b CVD, women 1.55 (0.58–4.13) 0.38 1.09 (0.48–2.51) 0.84 1.81 (1.21–2.72) 0.0040 þ
Rs7542281 F5 Additive
a Stroke, women 8.59 (1.45–50.84) 0.018 2.25 (0.24–21.29) 0.48 13.51 (2.82–64.77) 0.0011 þ
Rs2269648 F5 Additive
b Stroke, women 2.16 (0.31–15.15) 0.439 1.94 (0.16–24.12) 0.61 11.51 (2.25–58.83) 0.0034 þ
Rs6025 F5 Dominant
a Stroke, men Very rare
d Very rare
d 4.47 (1.63–12.29) 0.0037 þ
Rs1401296 PROC Recessive
a Stroke, men 2.44 (9.93–6.43) 0.072 2.07 (0.99–4.34) 0.054 2.84 (1.32–6.12) 0.0077 þ
Rs5030347 ICAM1 Recessive
a Death, men 1.76 (0.77–3.99) 0.18 2.55 (1.61–4.07) 0.000084 2.28 (1.55–3.36) 0.000029 þ
Rs1401296 PROC Dominant
a CVD, women 1.63 (0.86–3.08) 0.14 1.44 (0.81–2.57) 0.21 1.57 (1.03–2.04) 0.036  
Rs1401296 PROC Recessive
a CVD, men 1.50 (0.92–2.44) 0.11 1.31 (0.86–2.00) 0.20 1.43 (1.03–2.00) 0.035  
Rs6025 F5 Dominant
a Stroke, all 1.83 (0.64–5.26) 0.26 1.80 (0.61–5.31) 0.29 2.98 (1.20–7.41) 0.0191  
Rs5030347 ICAM1 Recessive
a CHD, men 1.51 (0.65–4.23) 0.11 1.10 (0.49–2.12) 0.28 1.88 (1.07–3.31) 0.028  
Covariates: age at baseline, (sex, cohort), smoking, hypertension, TC/HDL, BMI, diabetes, and CRP. The allele designated as the risk allele was coded 1 and the other allele 0.
aMinor allele is the risk allele.
bMajor allele is the risk allele.
cFDR: rejecting the null hypothesis for those with ‘‘þ’’ assures that the false-discovery rate ,10% in the combined analysis.
dCould not be analyzed in separate cohorts (number of cases ,10).
CI, confidence interval.
doi:10.1371/journal.pgen.0030120.t005
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tree by one or more traditional risk factors, such as
cholesterol level, BMI, or diabetes. This ﬁts well the current
understanding of the nature of the complex diseases: setting
aside some rare, strictly familial cases of CVD, the vast
majority of cardiovascular diseases are likely to be charac-
terized by several low-predisposing genes and their possible
interactions. In these cases, the traditional phenotypic risk
factors play a stronger role, and genetic factors are more
likely to lurk in the background. Classiﬁcation-trees could
therefore prove powerful also in determining subsets,
‘‘branches,’’ of individuals among whom the genetic variants
are especially evident risk factors. For example, the F5 Leiden
mutation has been suggested to be associated with CVD
among young women with an unhealthy lifestyle [29].
Our study identiﬁed several thrombosis-related risk var-
iants—both single SNPs and their pair-wise combinations—
for coronary events, ischemic strokes, and total mortality,
showing consistent association in two independently selected
Finnish population cohorts. Thrombosis is a central step in
the pathogenesis of myocardial infarction and ischemic
stroke. The ruptured wall of a coronary plaque is covered
with thrombosis leading either to local obstruction of
circulation or emboli traveling in more peripheral arterial
branches. Thus, variants in thrombosis genes are also
biologically relevant risk factors for coronary and stroke
events. Our observations on various allelic combinations
from several genes associating with CVD events highlight the
importance of wide-perspective studies concentrating on
numerous genes and their allelic variants to explore the
genetic background of any complex trait. One should
proceed cautiously when drawing biological conclusions from
statistical interaction models: the underlying biological
processes are likely to be highly complex, and evidence of
combined effects in a statistical sense fails to do justice to this
complexity. Our results indicate, however, that SNP combi-
nations may reveal risk variants that could remain unnoticed
when one is concentrating purely on single SNPs; SNP
combinations could therefore be one step forward in the
study of complex traits. Here, the CVD-associated variants of
the candidate genes, excluding the Leiden mutation, repre-
sent either intronic or intragenic SNPs, likely linked to other,
functional variants contributing to the true disease predis-
position.
Studies on the F5 Leiden mutation in arterial thrombosis
have been controversial [30], but a recent meta-analysis
suggests that the F5 Leiden mutation contributes signiﬁcantly
to coronary events [31]. The F5 Leiden mutation also
associated with ischemic stroke in children [32]. In our study,
men carrying the risk (minor) allele of F5 Leiden were at a
4.47-fold increased risk for ischemic stroke, and a suggestive
ﬁnding emerged when women were included in the analysis.
The Leiden mutation also contributed to CVD risk in men
jointly with a THBD SNP rs6048519. Addressing potential
Figure 2. Schematic Overview of the Interplay of Traditional Cardiovas-
cular Risk Factors and Genetic Variants Contributing to Disease Risk in
Our Study Sample
doi:10.1371/journal.pgen.0030120.g002
Table 6. Association of Pair-Wise SNP Combinations with the Endpoints in Time-to-Event Analysis
SNP Gene Inheritance Model Group FINRISK-92 FINRISK-97 Combined FDR c
HR (CI 95%) p-Value HR (CI 95%) p-Value HR (CI 95%) p-Value
Rs7542281 3 Rs1042580 F5/THBD Recessive
a/Dominant
a CHD, women 4.51 (1.40–14.54) 0.012 7.14 (2.09–24.36) 0.0017 4.45 (1.94–10.19) 0.00042 þ
Rs5030341 3 Rs1401296 ICAM1/PROC Dominant
a/Dominant
a Death, men 2.53 (1.03–6.20) 0.043 2.68 (1.50–4.76) 0.00081 1.63 (1.18–2.24) 0.0028 þ
Rs2269648 3 Rs1401296 F5/PROC Dominant
b/Dominant
a Death, men 1.20 (0.86–1.66) 0.28 1.07 (0.80–1.44) 0.65 1.80 (1.18–2.76) 0.0069 þ
Rs5030347 3 Rs1401296 ICAM1/PROC Recessive
a/Dominant
a CHD, women 4.29 (0.38–47.97) 0.24 1.50 (0.22–10.08) 0.68 2.08 (1.21–3.57) 0.0083  
Rs7542281 3 Rs1401296 F5/PROC Recessive
a/Dominant
a CVD, all 1.51 (0.94–2.44) 0.091 1.50 (1.02–2.21) 0.037 1.49 (1.11–2.01) 0.009  
Rs6025 3 Rs6048519 F5/THBD Dominant
a/Dominant
a CVD, men 1.53 (0.76–3.08) 0.23 5.09 (1.39–18.68) 0.014 2.80 (1.42–5.53) 0.0029  
Rs7542281 3 Rs1401296 F5/PROC Recessive
a/Dominant
a Stroke, all 3.00 (1.23–7.31) 0.016 2.00 (0.93–4.32) 0.077 2.69 (1.35–5.35) 0.0050  
Rs1401296 3 Rs6048519 PROC/THBD Recessive
a/Dominant
a Stroke, men 1.38 (0.33–5.76) 0.66 3.13 (1.06–9.27) 0.039 3.42 (1.30–8.99) 0.013  
Covariates: age at baseline, (sex, cohort), smoking, hypertension, rchol, BMI, diabetes, and CRP. The allele stated as the risk allele was coded as 1 and the other allele as 0. Estimates of the
SNPs contributing to the combinations are listed in Table S3.
aMinor allele is the risk allele.
bMajor allele is the risk allele.
cFDR: rejecting the null-hypothesis for those with ‘‘þ’’ assures that the false-discovery rate ,10% in the combined analysis.
CI, confidence interval.
doi:10.1371/journal.pgen.0030120.t006
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impact of the Leiden mutation, requires very large datasets
[31]. Our earlier results implied that in our study cohorts
THBD variants alone seemed to play no role in CVD [15], but
our new data from this study suggest that THBD may
contribute to CVD in combination with other risk factors.
Podgoreanu and colleagues reported an association of ICAM1
SNP rs5498 with postoperative myocardial infarction [19].
This SNP was in our population in strong LD (r
2 ¼ 0.82) with
SNP rs3093030, but with no association with CVD. The wide
conﬁdence intervals in the analyses of female stroke cases
reﬂect the need for larger study cohorts. In the present study,
the number of female stroke participants was especially
limited.
This is, to our knowledge, the ﬁrst study to cover all known
common allelic variants in F5, ICAM1, PROC, and THBD
genes, analyzing them as a physiological ‘‘pathway’’ entity and
assessing their relationship with the traditional CVD risk
factors. Multiple testing is an emerging issue in all complex
genetics studies comprising several markers. We adjusted the
ﬁndings of the ﬁnal analysis step for multiple testing using
the FDR, although this does not adjust for the fact that the
earlier selection of SNPs by use of classiﬁcation-trees was
done on the same dataset. We chose to use 10% as a limit in
the FDR analyses, stating that with this limit, 90% of the
ﬁndings are expected to be true positives, whereas 10% could
still be false positives. In addtition, the sensitivity analysis
suggested that the classiﬁcation-tree approach was able to
select the informative SNPs, excluding the less informative
ones. The major strength of this study is to further minimize
the possibility of false-positive ﬁndings by requiring consis-
tency in the ﬁndings in two separate cohorts of the same
population. However, these results still need replication in
other independent studies and populations. The major
limitation of this study is its cohort size; studies comprising
several hundred cases in each category are needed to
profoundly address gene–gene interactions, especially once
these types of analyses are reaching genome-wide datasets of
thousands of genes. Another limitation of the study sample is
the lack of plasma concentrations of the hemostatic factors.
In conclusion, combining data from several genes encoding
components of the same biological pathway and analyzing the
impact of genes together with other relevant risk factors may
prove useful in regard to studying diseases with polygenic
structures. Currently, sensible ways are called for to analyze
the overwhelming information load produced by studies
containing various genes and many variants. Our approach
provides one example for selecting the informative variants
from the background. Our results from the thrombosis
cascade of four genes shed light on the interplay of these
gene variants’ roles in arterial thrombosis.
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